Validation of existing markers such as p53, EGFR, PCNA and LOH at 3p, 9p and 15q. Identification of new biomarkers according to analysis of different pathways. Standardization evaluation of methods to optimize comparability of studies from different groups. Mechanistic studies of different cell lines. Investigations of differentiation inducers.
Funding is essential for tissue banking, informatics and protocol development for specimen handling.
Negative functional impact of tumor course or treatment. Identification of most effective inhibitors such as anti- vascular endothelial growth factor agents. Evaluation of vascular density as a predictor of outcome. Development of better models Transgenic mice, murine tumors, and human tumors in nude mice. Human fresh or frozen tissue from tumors at various stages of progression, which would be banked and correlated with a search for existing or new predictive markers or for testing new therapeutics.